Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer

Expert Review of Anticancer Therapy

Volumn 10, Issue 6, 2010, Pages 795-805

  Del Campo, Josep M ^a   Muoz Couselo, Eva ^a   Diaz De Corcuera, Isabella ^a   Oaknin, Ana ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Liposomal doxorubicin; Ovarian cancer; Platinum sensitivity; Trabectedin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; CYTOCHROME P450 3A4; DEXAMETHASONE; DOXORUBICIN; GEMCITABINE; KETOCONAZOLE; PACLITAXEL; TOPOTECAN; TRABECTEDIN; TROLEANDOMYCIN; 1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANTIANGIOGENIC THERAPY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPOALBUMINEMIA; HYPONATREMIA; INJECTION SITE ERYTHEMA; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; RECURRENT CANCER; REVIEW; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VOMITING; CLINICAL TRIAL (TOPIC); FEMALE; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DIOXOLES; DOXORUBICIN; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS; TETRAHYDROISOQUINOLINES;

EID: 77953756810     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.59     Document Type: Review

References (76)

1. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin. Surg. Oncol. 19(1), 3-10 (2000).
2. Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist 5(1), 26-35 (2000).
3. Fung MF, Johnston ME, Eisenhauer EA, Elit L, Hirte HW, Rosen B. Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum - a systematic review of the evidence from randomized trials. Eur. J. Gynaecol. Oncol. 23(2), 104-110 (2002).
4. Wakabayashi MT, Lin PS, Hakim AA. The role of cytoreductive/debulking surgery in ovarian cancer. J. Natl Compr. Canc. Netw. 6(8), 803-810 (2008).
5. Viens P, Petit T, Yovine A et al. A Phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann. Oncol. 17(3), 429-436 (2006).
6. Schwartz PE. Cytoreductive surgery in the management of ovarian cancer. Oncology 22(9), 1025-1033 (2008).
7. Parmar MK, Ledermann JA, Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361(9375), 2099-2106 (2003).
8. Pfisterer J, Plante M, Vergote I et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24(29), 4699-4707 (2006).
9. Pujade-Lauraine SME, Kaern J, Gebski V et al. A randomized, Phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG). J. Clin. Oncol. 27, 18(Suppl.), (2009) (Abstract LBA5509).
10. Ferrero JM, Weber B, Geay JF et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO Phase II trial. Ann. Oncol. 18(2), 263-268 (2007).
11. Rose PG, Maxson JH, Fusco N, Mossbruger K, Rodriguez M. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. Gynecol. Oncol. 82(2), 323-328 (2001).
12. Kose MF, Meydanli MM, Tulunay G. Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma. Expert Rev. Anticancer Ther. 6(3), 437-443 (2006).
13. Katsumata N, Yasuda M, Takahashi F et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a Phase 3, open-label, randomised controlled trial. Lancet 374(9698), 1331-1338 (2009).
14. Bookman MA. Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a Phase III randomized trial of the Gynecologic Oncology Group (GOG-0182). Semin. Oncol. 29(1 Suppl. 1), 20-31 (2002).
15. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19(14), 3312-3322 (2001).
16. Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. Br. J. Cancer 100(1), 1-7 (2009).
17. Monk BJ, Herzog T, Kay S et al. A randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC). Ann. Oncol. 19(Suppl. 8), (2008) (Abstract LBA4).
18. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 66(16), 8155-8162 (2006).
19. Carter NJ, Keam SJ. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 67(15), 2257-2276 (2007).
20. Valoti G, Nicoletti MI, Pellegrino A et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin. Cancer Res. 4(8), 1977-1983 (1998).
21. Hendriks HR, Fiebig HH, Giavazzi R, Langdon SP, Jimeno JM, Faircloth GT. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann. Oncol. 10(10), 1233-1240 (1999).
22. Morioka H, Weissbach L, Vogel T et al. Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clin. Cancer Res. 9(3), 1211-1217 (2003).
23. Donald S, Verschoyle RD, Greaves P et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. Cancer Res. 63(18), 5902-5908 (2003).
24. Sessa C, Cresta S, Noberasco C et al. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. Eur. J. Cancer 45(12), 2116-2122 (2009).
25. Sessa C, Perotti A, Noberasco C et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur. J. Cancer 45(7), 1153-1161 (2009).
26. von Mehren M, Schilder RJ, Cheng JD et al. A Phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann. Oncol. 19(10), 1802-1809 (2008).
27. Riccardi A, Meco D, Ubezio P et al. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft. Anticancer Drugs 16(8), 811-815 (2005).
28. D'Incalci M, Colombo T, Ubezio P et al. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur. J. Cancer 39(13), 1920-1926 (2003).
29. Meco D, Colombo T, Ubezio P et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother. Pharmacol. 52(2), 131-138 (2003).
30. Manara MC, Perdichizzi S, Serra M et al. The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71. Int. J. Oncol. 27(6), 1605-1616 (2005).
31. Marchini S, Marrazzo E, Bonomi R et al. Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743. Eur. J. Cancer 41(2), 323-333 (2005).
32. Scotto KW, Johnson RA. Transcription of the multidrug resistance gene MDR1: a therapeutic target. Mol. Interv. 1(2), 117-125 (2001).
33. Forouzesh B, Hidalgo M, Chu Q et al. Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies. Clin. Cancer Res. 15(10), 3591-3599 (2009).
34. Beumer JH, Rademaker-Lakhai JM, Rosing H et al. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer. Cancer Chemother. Pharmacol. 59(6), 825-837 (2007).
35. van Kesteren C, Cvitkovic E, Taamma A et al. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a Phase I dose-finding study. Clin. Cancer Res. 6(12), 4725-4732 (2000).
36. Twelves C, Hoekman K, Bowman A et al. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur. J. Cancer 39(13), 1842-1851 (2003).
37. van Kesteren C, Twelves C, Bowman A et al. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a Phase I study. Anticancer Drugs 13(4), 381-393 (2002).
38. Del Campo JM, Roszak A, Bidzinski M et al. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann. Oncol. 20(11), 1794 - 1802 (2009).
39. Krasner CN, McMeekin DS, Chan S et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br. J. Cancer 97(12), 1618-1624 (2007).804
40. Taamma A, Misset JL, Riofrio M et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J. Clin. Oncol. 19(5), 1256-1265 (2001).
41. Ryan DP, Supko JG, Eder JP et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin. Cancer Res. 7(2), 231-242 (2001).
42. Villalona-Calero MA, Eckhardt SG, Weiss G et al. A Phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin. Cancer Res. 8(1), 75-85 (2002).
43. Gabizon A, Catane R, Uziely B et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54(4), 987-992 (1994).
44. Vaage J, Barbera-Guillem E, Abra R, Huang A, Working P. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 73(5), 1478-1484 (1994).
45. Campos SM, Penson RT, Mays AR et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol. Oncol. 81(2), 206-212 (2001).
46. Ferrandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J. Clin. Oncol. 26(6), 890-896 (2008).
47. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 15(3), 987-993 (1997).
48. Gordon AN, Granai CO, Rose PG et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J. Clin. Oncol. 18(17), 3093-3100 (2000).
49. Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Phase II trial of liposomal doxorubicin (40 mg/ m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol. Oncol. 78(3 Pt 1), 369-372 (2000).
50. Arcuri C, Sorio R, Tognon G et al. A Phase II study of liposomal doxorubicin in recurrent epithelial ovarian carcinoma. Tumori 90(6), 556-561 (2004).
51. Lorusso D, Naldini A, Testa A, D'Agostino G, Scambia G, Ferrandina G. Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. May a new treatment schedule improve toxicity profile? Oncology 67(3-4), 243-249 (2004).
52. Chou HH, Wang KL, Chen CA et al. Pegylated liposomal doxorubicin (Lipo- Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up. Gynecol. Oncol. 101(3), 423-428 (2006).
53. Wilailak S, Linasmita V. A study of pegylated liposomal doxorubicin in platinum-refractory epithelial ovarian cancer. Oncology 67(3-4), 183-186 (2004).
54. Mutch DG, Orlando M, Goss T et al. Randomized Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 25(19), 2811-2818 (2007).
55. Katsumata N, Fujiwara Y, Kamura T et al. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group. Jpn. J. Clin. Oncol. 38(11), 777-785 (2008).
56. du Bois A, Pfisterer J, Burchardi N et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: a prospective Phase II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol. Oncol. 107(3), 518-525 (2007).
57. Weber B, Lortholary A, Mayer F et al. Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group Phase II trial. Anticancer Res. 29(10), 4195-4200 (2009).
58. Cohen RB, Schilder RJ, Cheng J et al. Final results of a combination study between trabectedin and pegylated liposomal doxorubicin (PLD) in patients with advanced malignancies. J. Clin. Oncol. 23(Suppl. 16), (2005) (Abstract 3074).
59. Izbicka E, Lawrence R, Raymond E et al. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann. Oncol. 9(9), 981-987 (1998).
60. Jimeno JM. A clinical armamentarium of marine-derived anti-cancer compounds. Anticancer Drugs 13(Suppl. 1), S15-S19 (2002).
61. McMeekin DS, Krasner C, Chan S et al. Final results of a Phase II study of weekly trabectedin in second/third line ovarian carcinoma. J. Clin. Oncol. 23(Suppl. 16), (2005) (Abstract 5011).
62. Sessa C, De Braud F, Perotti A et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J. Clin. Oncol. 23(9), 1867-1874 (2005).
63. Del Campo J, Roszak A, Ciuleanu T et al. Phase II open label randomized study of trabectedin (T) given as two different dosing schedules in women with platinum-sensitive, recurrent ovarian carcinoma: preliminary results. J. Clin. Oncol. 24(18 Suppl.) (2006) (Abstract 5031).
64. McMeekin S, del Campo JM, Colombo N et al. Trabectedin (T) in relapsed advanced ovarian cancer (ROC): a pooled analysis if three Phase II studies. J. Clin. Oncol. 25(Suppl. 18), (2007) (Abstract 5579).
65. Markman M. Hypersensitivity reactions: an increasingly recognized toxicity of platinum agents. Oncology 76(4), 229-230 (2009).
66. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet. Gynecol. 107(6), 1399-1410 (2006).
67. Allavena P, Signorelli M, Chieppa M et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res. 65(7), 2964-2971 (2005).
68. Cvetkovic RS, Figgitt DP, Plosker GL. ET-743. Drugs 62(8), 1185-1192 (2002).
69. Stevens EV, Nishizuka S, Antony S et al. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers. Mol. Cancer Ther. 7(1), 10-18 (2008).
70. Zelek L, Yovine A, Brain E et al. A Phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br. J. Cancer 94(11), 1610-1614 (2006).
71. McMeekin DS, Lisyanskaya A, Crispens M et al. Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter Phase II study. Gynecol. Oncol. 114(2), 288-292 (2009).
72. Tewari D, Saffari B, Cowan C, Wallick AC, Koontz MZ, Monk BJ. Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma. Gynecol. Oncol. 102(3), 421-424 (2006).
73. Amant F, Coosemans A, Renard V, Everaert E, Vergote I. Clinical outcome of ET-743 (Trabectedin; Yondelis) in high-grade uterine sarcomas: report on five patients and a review of the literature. Int. J. Gynecol. Cancer 19(2), 245-248 (2009).
74. Takahashi N, Li W, Banerjee D et al. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res. 62(23), 6909-6915 (2002).
75. Takahashi N, Li WW, Banerjee D, Scotto KW, Bertino JR. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin. Cancer Res. 7(10), 3251-3257 (2001).
76. NCCN clinical practice guidelines in oncology: ovarian cancer (online) www.nccnorg/professionals/physician-gls/ PDF/ovarianpdf 2009